Evaluation of Contraindications and Efficacy of Oral Beta Blockade Before Computed Tomographic Coronary Angiography
Multidetector computed tomographic coronary angiography (CTA) image quality is inversely related to the heart rate (HR). As a result beta-blocking medication is routinely administered before investigation. In the present study, the use, contraindications, and efficacy of prescan beta blockade with regard to HR reduction and CTA image quality were assessed. In 537 patients referred for CTA, the baseline HR and blood pressure were measured on arrival, and contraindications for beta blockade were noted. Unless contraindicated, a single dose of metoprolol was administered orally 1 hour before data acquisition in patients with a HR of ≥65 beats/min according to a predefined medication protocol. After 1 hour, the HR was remeasured. A total of 283 patients (53%) had a HR of ≥65 beats/min. In this group, beta blockade was contraindicated in 46 patients (16%). Metoprolol was administered to the remaining 237 patients. However, 26 patients (11%) received suboptimal (lower dose than prescribed by protocol) beta blockade because of contraindications. Of the 211 patients receiving optimal beta blockade, 57 (27%) did not achieve the target HR. Of the patients with contraindications to beta blockade, 43 (60%) did not achieve the target HR. Compared to patients with optimal HR control, those receiving no or suboptimal beta blockade because of contraindications had significantly fewer examinations of good image quality (40% vs 74%, p <0.001), and significantly more examinations of poor image quality (20% vs 6%, p <0.001). In conclusion, most patients require HR reduction before CTA. Contraindications to beta blockade are present in a substantial proportion of patients. This results in suboptimal HR control and image quality, indicating the need for alternative approaches for HR reduction.
To access this article, please choose from the options below
Dr. de Graaf is co-supported by the Dutch Technology Foundation STW (Utrecht, The Netherlands), Applied Science Division of The Netherlands Organisation for Scientific Research (Den Haag, The Netherlands) and grant 10084 from the Technology Program of the Ministry of Economic Affairs. Dr. van Velzen is supported by grant 2007B223 from The Netherlands Heart Foundation (The Hague, The Netherlands). Dr. Schalij has received research grants from Boston Scientific (Natick, Massachusetts), Medtronic (Minneapolis, Minnesota), and Biotronik (Berlin, Germany). Dr. Bax has received research grants from Medtronic (Minneapolis, Minnesota), Boston Scientific (Natick, Massachusetts), Bristol-Myers Squibb Medical Imaging (New York, New York), St. Jude Medical (St. Paul, Minnesota), GE Healthcare (Chalfont St. Giles, United Kingdom), Biotronik (Berlin, Germany), and Edwards Lifesciences (Irvine, California).
PII: S0002-9149(09)02675-7
doi:10.1016/j.amjcard.2009.10.058
© 2010 Elsevier Inc. All rights reserved.
